A reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease

ISRCTN ISRCTN96337233
DOI https://doi.org/10.1186/ISRCTN96337233
Secondary identifying numbers N/A
Submission date
06/11/2002
Registration date
06/11/2002
Last edited
28/10/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Study website

Contact information

Prof Richard Gray
Scientific

University of Birmingham Clinical Trials Unit
University of Birmingham
Park Grange
1 Somerset Road
Edgbaston
Birmingham
B15 2RR
United Kingdom

Phone +44 (0)121 415 9100
Email r.gray@bham.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleA reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease
Study acronymAD2000
Study hypothesisTo assess the efficacy and safety of donepezil and aspirin in Alzheimer's Disease.
Ethics approval(s)Not provided at time of registration
ConditionAlzheimer's disease
InterventionPatients are randomised to receive donepezil 5 mg or placebo for the first 12 weeks of the trial.

Those who complete 12 weeks of treatment are re-randomised to receive 48 weeks of donepezil or placebo from week 13 onwards, with donepezil dose sub-randomised between 5 and 10 mg.

Eligible patients (those with no clear indication for, or clear indication against, aspirin) are also randomised at entry between 75 mg enteric-coated aspirin daily or aspirin avoidance.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Donepezil, aspirin
Primary outcome measure1. Cognition (assessed with the mini-mental state examination [MMSE])
2. Functional ability (assessed with the Bristol activities of daily living scale [BADLS])

Patients were assessed at 12-week intervals in the first year and once each year thereafter.
Secondary outcome measures1. Time to formal domiciliary or institutional care
2. Progress of disability
3. Behavioural symptoms
4. Caregiver wellbeing
5. Care time

Patients were assessed at 12-week intervals in the first year and once each year thereafter.
Overall study start date01/01/2000
Overall study end date01/01/2004

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexBoth
Target number of participants310
Participant inclusion criteria1. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnosis of Alzheimer's disease, with or without evidence of vascular dementia
2. Mild to moderate Alzheimer's disease (Mini Mental State Examination [MMSE] score 10 - 26)
3. No definite contraindication to, or clear indication for, donepezil
4. Not in residential care
5. Regular carer
6. Not have already taken donepezil or any other cholinergic enhancing agent
Participant exclusion criteriaNot provided at time of registration
Recruitment start date01/01/2000
Recruitment end date01/01/2004

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Birmingham Clinical Trials Unit
Birmingham
B15 2RR
United Kingdom

Sponsor information

West Midlands NHS Research & Development Executive (UK)
Government

Bartholomew House
142 Hagley Road
Birmingham
B16 9PA
United Kingdom

Website http://www.doh.gov.uk/research/wmro/new.htm

Funders

Funder type

Government

West Midlands NHS Research & Development Executive (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 26/06/2004 Yes No
Results article 01/01/2008 Yes No

Editorial Notes

28/10/2022: Internal review.